Age Labs is a Norwegian molecular diagnostics company that discovers, develops and commercializes biomarkers for the early detection of age-related diseases. We offer a service for evaluating epigenetic drug effects for use in clinical trials. Our biomarker discovery pipeline includes a biological age predictor and a test predicting the severity of COVID-19 infection. To date, we have raised 30 MNOK in private and public funding, and became a Nordic Startup Awards finalist in 2020. We are supported by strong commercial and R&D partners, including Oslo University Hospital, the Norwegian Institute of Public Health, Merck Group and Fürst Medical Laboratory. Our mission is to develop novel precision biomarkers for the early detection of age related diseases to extend the human healthspan.